Aurora Cannabis expands medical portfolio across global markets

Aurora Cannabis Inc. (NASDAQ: ACB) announced new medical cannabis product launches across Canada, Europe and Australia. The company stated the products will roll out between now and June 2026.

The Edmonton-based company's expanded offerings include dried flower, pre-rolls and pastilles. In Germany, Aurora will introduce San Raf Pink OG Kush dried flower with THC levels of 25-27% and Daily Special Lemon Sorbet with 21% THC. Poland will receive Cannabis flos Aurora Electric Honeydew with 27% THC and Chemango Kush with 29% THC.

Australia will see the launch of pastille products, including Black Raspberry Pastilles containing THC, CBD and CBN, and Blood Orange Pastilles with multiple cannabinoids. In Canada, the company will release WMMC Seasonal Stash products and San Raf branded items in various formats.

"As our global medical business continues to grow, our focus remains on delivering consistency and reliability across the markets we serve," said Lana Culley, VP Innovation & International Operations at Aurora. "By expanding our offerings in key countries, we're responding to clear patient and prescriber demand with products that meet local regulatory standards."

Aurora operates GMP-certified manufacturing facilities in Canada and Germany. The company serves medical and consumer markets across multiple countries including Canada, Europe, Australia and New Zealand. Aurora's brands include Aurora, MedReleaf, Pedanios, IndiMed, San Raf, Tasty's and Whistler Medical Marijuana Co.

The information is based on a company press release statement.

You May Also Be Interested In

• Lockheed, RTX, Boeing, L3Harris expected to meet with Trump - WSJ
• CNH Industrial (CNH) call put ratio 1 call to 8.3 puts with a focus on 1722 contracts of December 10 puts
• Apple investigating exposure to Tata Electronics data breach, full analysis underway - Reuters